pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Prognostic factors of progression-free survival (PFS)
Variables | Univariate analysis (Log rank test) | Multivariable analysis (Cox proportional hazard model) | ||||
---|---|---|---|---|---|---|
Number of patients (Progressed/Total) | Median PFS (months) | HR | 95% CI | |||
Age, years | ||||||
<65 ≥65 |
76/93 55/63 |
8.27 8.40 |
0.250 | |||
Sex | ||||||
Male Female |
103/121 28/35 |
8.40 8.27 |
0.563 | |||
KPSa | ||||||
<80% ≥80% |
12/12 87/108 |
10.00 2.90 |
<0.001 | 3.46 | 1.18–10.12 | 0.023 |
Nephrectomy | ||||||
Yes No |
112/135 19/21 |
9.10 6.17 |
0.066 | |||
Histology | ||||||
Non-clear cell Clear cell |
7/8 124/148 |
5.70 8.40 |
0.185 | |||
Prior therapy | ||||||
Yes No |
34/41 97/115 |
8.87 8.23 |
0.298 | |||
Time from diagnosis to systemic treatment | ||||||
<1 year ≥1 years |
84/94 46/61 |
7.47 11.33 |
0.004 | 2.48 | 1.10–5.60 | 0.028 |
Number of metastases | ||||||
1 ≥2 |
47/60 84/96 |
11.33 7.70 |
0.013 | |||
Anemia | ||||||
Yes No |
77/87 54/69 |
10.97 7.83 |
0.049 | |||
Thrombosis | ||||||
Yes No |
14/16 117/140 |
6.07 9.00 |
0.118 | |||
Neutrophilia | ||||||
Yes No |
8/10 123/146 |
4.33 8.40 |
0.775 | |||
Hypercalcemia | ||||||
Yes No |
16/18 115/138 |
3.73 9.43 |
0.003 | |||
Elevated LDH | ||||||
Yes No |
3/4 64/75 |
1.97 8.03 |
0.810 | |||
Pre-treatment NLR | ||||||
≥3 >3 |
92/113 39/43 |
9.80 5.30 |
0.001 | |||
Sunitinib-induced hypothyroidism | ||||||
Overt Subclinical Euthyroid |
40/51 28/35 63/70 |
12.20 6.17 6.07 |
0.001 | 0.38 | 0.16–0.88 | 0.024 |
Sunitinib-induced hypertension | ||||||
Yes No |
35/48 96/108 |
12.60 7.00 |
<0.001 | |||
Sunitinib-induced proteinuria | ||||||
Yes No |
50/63 81/93 |
10.47 7.83 |
0.042 | |||
Sunitinib-induced renal insufficiency | ||||||
Yes No |
19/23 112/133 |
10.50 8.23 |
0.107 |
CI: confidence interval, HR: hazard ratio, KPS: Karnofsky performance score, LDH: lactate dehydrogenase, NLR: neutrophil lymphocyte ratio,
PFS: progression-free survival
a)Evaluated in 120 patients, b)Evaluated in 79 patients